Drug Trial Radar · NCT03316729
DS-9231 in Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)
Last checked: Nov 19, 2026Latest source record: Dec 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jan 2018
Primary completion
Feb 2020
Study completion Feb 2020
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- First posted
- Oct 20, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate safety and initial effectiveness of DS-9231 when taken together with current standard of care. Evaluation will be done with low, medium and then high doses of DS-9231 versus placebo, in participants with medium-risk acute pulmonary embolism.
Conditions
- Pulmonary Embolism
Interventions
DS-9231Drug
DS-9231 in saline solution for intravenous infusion
PlaceboDrug
Placebo is matching saline solution for intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in total thrombus volumeTime frame: Baseline, 48-96 hours after study drug administration
- Percentage of participants with various gradations of decrease in total thrombus volumeTime frame: Baseline, 48-96 hours after study drug administration
- Number of participants with major or clinically relevant nonmajor bleedingTime frame: within 7 days after study drug administration
- Number of participants with adverse eventsTime frame: within 30 days after study drug administration
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.